Skip to content

Concordance Between Buccal Cavity Swab and Nasopharyngeal Swab for SARS-CoV-2 (COVID-19) Detection by RT-PCR and ELISA

Evaluating the Use of Flavour-stimulated Oral Fluids Collection for Severe Acute Respiratory Syndrome Coronavirus 2 Detection by Reverse Transcriptase Polymerase Chain Reaction and Enzyme Linked Immunosorbent Assay - a Concordance Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04732637
Enrollment
300
Registered
2021-02-01
Start date
2021-03-31
Completion date
2021-08-31
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

COVID19, Nasopharyngeal Swab, Self Collection, Chewable, Lollipop

Brief summary

Nasopharyngeal Swabs (NPS) used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can cause mild to severe discomfort in addition to increasing the risk of transmission. The present study evaluates Test At Home's proprietary self-collection method based on a chewable buccal cavity swab (lollipop) that stimulates oral fluid collection. The novel method is compared against a contemporary nasal swab collected by a qualified healthcare worker.

Detailed description

Nasopharyngeal Swabs (NPS) are used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. It also increases the risk of transmission and other challenges. The present study aims to develop a more convenient method of collecting samples for COVID-19 testing. The study is based on the hypothesis that saliva collection using the proprietary flavour-stimulated 'Lollipop' swab (LPS) can be a more viable alternative to NPS. The study aims to establish the comparative efficacy of SARS-Cov-2 infection assessment using Test At Home's proprietary lollipop buccal cavity swab (LPS) that simulates oral fluid collection via flavouring and mastication (self-collection) using the contemporary nasal swab collection (by health worker) as standard. For the present study, 300 pairs of matched nasopharyngeal swab (NPS) (health care worker collected) and simulated oral fluid specimens (self-collected) will be obtained from 150 Coronavirus Disease -19 (COVID-19) positive patients and 150 COVID 19 negative individuals. Test Method 1: Self-collected Test At Home's proprietary lollipop buccal cavity swab with Viral Transport Medium (VTM) will be evaluated using the Standard 'TaqPath™' COVID-19 Conformité Européenne - In Vitro Diagnostic (CE-IVD) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) which is approved by the Indian Council of Medical Research (ICMR) Test Method 2: Self-collected Test At Home's proprietary lollipop buccal cavity swab with VTM will be evaluated using National University of Singapore (NUS) developed Enzyme Linked Immunosorbent Assay (ELISA) Method. Active Comparator : Health worker collected Nasopharyngeal Swab (NPS) with VTM which will be evaluated using the Standard TaqPath™ COVID-19 CE-IVD RT-PCR which is approved by the Indian Council of Medical Research (ICMR). The diagnostic performance of using NPS and Oral fluids will be statistically compared to determine concordance of positive and negative findings and establish the performance characteristics of the Test Methods.

Interventions

DIAGNOSTIC_TESTTest At Home's Proprietary Lollipop Buccal Cavity Swab

Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM.

Sponsors

Test At Home Pte. Ltd
CollaboratorUNKNOWN
National University of Singapore
CollaboratorOTHER
Datar Cancer Genetics Limited
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

1. Males and Females 2. Adults 3. Known COVID-19 positive by RTPCR (with active infection) OR Known COVID-19 negative by RTPCR (tested within 7 days) 4. Provision of Informed Consent 5. Willing to provide Nasopharyngeal Swab as well as Buccal Cavity Swab

Exclusion criteria

1. Pediatric patients. 2. Inability to provide Informed Consent. 3. Inability to provide Nasopharyngeal Swab and / or Buccal Cavity Swab.

Design outcomes

Primary

MeasureTime frameDescription
Concordance between buccal cavity swab and contemporary nasal swab.Baseline / Day 0 (At first collection)Three-way concordance of SARS-Cov-2 infection assessment between Test At Home's Lollipop buccal cavity swab (assessed by RTPCR and ELISA) and contemporary nasal swab (assessed by RTPCR).

Countries

India

Contacts

Primary ContactVineet Datta, MD
drvineetdatta@datarpgx.com+919911110457
Backup ContactDadasaheb Akolkar, PhD
dadasaheb.akolkar@datarpgx.com+917387705888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026